This study is testing a new drug called TUB-030 for adults with advanced solid tumors, including head and neck cancer (HNSCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). The main goals are to find out how safe TUB-030 is, what side effects it might cause, and the highest dose that can be given safely (maximum tolerated dose or MTD). Researchers will also see if TUB-030 works to treat these cancers. You might be able to join if you are 18 or older, have good organ function, and have waited a certain time after your last cancer treatment. This trial is looking to enroll about 250 participants.

Study design

This is an interventional study, meaning participants will receive the drug TUB-030. It aims to enroll 250 participants.

What's involved

You would receive TUB-030 intravenously (through a vein) every 3 weeks. You will also visit the clinic every 3 weeks for checkups and tests, and answer questionnaires about your symptoms.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from enrollment until 30 days after your last dose of TUB-030.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.